Clinical Trials Logo

Body Weight clinical trials

View clinical trials related to Body Weight.

Filter by:

NCT ID: NCT03745612 Completed - Obesity Clinical Trials

Time Restricted Feeding on Weight Loss and Cardio-protection (TREATY Trial)

TREATY
Start date: November 30, 2018
Phase: N/A
Study type: Interventional

Time restricted feeding (TRF) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. This is a randomized controlled trial to evaluate the effect of time restricted feeding (TRF) on weight loss and cardiometabolic risk factors in obese adults over 12 months compared to continuous energy restriction (CER).

NCT ID: NCT03738540 Completed - Weight Loss Clinical Trials

Pilot Trial of a Telephone Weight Loss, Nutrition, Exercise Study

WeLNES
Start date: August 29, 2018
Phase: N/A
Study type: Interventional

Many behavioral weight loss interventions have been developed, but still have significant limitations in terms of achieving clinically significant, sustained weight loss. A recent study incorporating Acceptance and Commitment Therapy (ACT) in a randomized clinical trial resulted in participants who attained significantly greater 12-month weight loss in the ACT arm than those assigned to standard behavioral treatment, suggesting that ACT may have the potential to improve behavioral weight loss outcomes. The investigators have developed a novel telephone-delivered version of the ACT behavioral weight loss intervention, based on proven success using ACT telephone counseling intervention for smoking cessation.

NCT ID: NCT03735706 Completed - Body Weight Clinical Trials

Relationship Between Contrast Media Volume and Tube Voltage in CT for Optimal Liver Enhancement, Based on Body Weight.

COMpLEx
Start date: December 13, 2018
Phase: N/A
Study type: Interventional

Computed Tomography (CT) is widely used in abdominal imaging for a variety of indications. Contrast media (CM) is used to enhance vascular structures and organ parenchyma. Attenuation of the liver makes it possible to recognize hypo- and hypervascular lesions, which are often invisible on unenhanced CT images. Lesions can only be detected in case they are large enough and the contrast with the background is high enough. Heiken et al. showed already in 1995 that a difference in Hounsfield Units (HU) of at least 50 HU is needed to be able to recognize liver lesions [1]. On the other hand, patients should not receive more CM than necessarily, because of possible underlying physiological effects [2-4]. Although there has been some controversy about this recently, there is no need to give patients more CM than needed, because of increased costs, no quality improvement and their might still be a relationship with contrast induced nephropathy (CIN) [5]. Recent publications suggested individualization of injection protocols that can be based on either total body weight (TBW) or lean body weight (LBW) [6-9]. In the investigators department an injection protocol based on TBW is currently used. Besides the CM injection parameters, scanner parameters are of influence on the attenuation as well. Because of recent technical developments it became possible to reach a good image quality (IQ) at lower tube voltages [10]. When the x-ray output comes closer to the 33 keV k-edge of Iodine, attenuation increases. In short, decreasing the tube voltage increases the attenuation of iodine. Scanning at a lower tube voltage therefore gives rise to even lower CM volumes. Lastly, it would be revolutionary to accomplish a liver enhancement that is homogenous, sufficient for lesion detection and comparable between patients and in the same patients, regardless of weight and scanner settings used.

NCT ID: NCT03732261 Terminated - Bone Loss Clinical Trials

Effects of Exercise and Yogurt on Bone Mineral Density and Immunological Factors in Human Milk: The MEEMA Study

MEEMA
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Obesity in America has risen to epidemic levels over the past 20 years. For women, childbearing itself could be a contributing factor to this high prevalence of excess weight. In addition, for women who breastfeed, lactation is a time of rapid bone loss due to hyperprolactinemia, amenorrhea, and increased bone turnover, especially in the lumbar spine and hip. The American Academy of Pediatrics recommends exclusive breastfeeding for the first 6 months, continue to at least 12 months with the introduction of complementary foods and up to 2 years. Breastfeeding helps reduce long term maternal weight retention from pregnancy, the risk of childhood obesity and provides a number of immunological factors to promote the immune system and gastrointestinal system of the neonate. Bone loss due to lactation is usually reversed with weaning; however, not all women recover from this bone loss which increases the risk of osteoporosis later in life. Weight bearing exercise and dairy intake (milk, yogurt, cheese) plus vitamin D supplementation may provide some protection from bone loss. Thus, the objective of this study is to promote long-term lifestyle changes that support healthy lifelong weight management through a community based exercise intervention and daily yogurt consumption program aimed at overweight- to- obese lactating postpartum women.

NCT ID: NCT03720938 Completed - Body Weight Clinical Trials

Effects of Active Video Games in Physically Inactive Children

AVGAME
Start date: February 2013
Phase: N/A
Study type: Interventional

Inactivity was reported to be high in children and considered to be the fourth common cause of death in all ages. The reason for children is usually the increasing indoor use of sedentary screen time. Active Video Games (AVG) have recently been introduced for decreasing the sedentary time for children and directing them to physical activity (PA) at home.The aim of this study is to show the quantitative effect of games on physical fitness parameters like weight, body mass index (BMI) and fat ratio (FR). The study also aims at the factors for motivation or continuance of the games as self-perception and enjoyment levels together with qualitative effects of games on satisfaction and attitude changes in inactive children.

NCT ID: NCT03720015 Completed - Body Weight Changes Clinical Trials

Concurrent Training and Nutritional Management in Cancer

Start date: July 20, 2017
Phase: N/A
Study type: Interventional

A case control study with before-after design. A concurrent training and a nutritional management intervention was offered by a patient with head and neck cancer, in order to compare outcomes related to strength and endurance performance and to body composition

NCT ID: NCT03718000 Completed - Obesity Clinical Trials

Daily Self-weighing and Holiday-associated Weight Gain in Adults

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

Background: Previous studies report 0.4-1.5kg of weight gain during the holiday season, which may contribute to annual weight gain. Purpose: To test whether daily self-weighing (DSW) can prevent holiday weight gain. Hypothesis: We hypothesized that daily self-weighing would effectively prevent weight and fat gain, and that individuals with overweight and obesity would respond most favorably to DSW.

NCT ID: NCT03717428 Completed - Weight Gain Clinical Trials

Preventing Age-Related Weight Gain in the Workplace With Daily Weighing

Weigh2Go
Start date: October 1, 2016
Phase: N/A
Study type: Interventional

To examine the effectiveness of daily weighing to prevent age-related weight gain.

NCT ID: NCT03712462 Completed - Weight Loss Clinical Trials

Improving Weight Loss Outcomes for Binge Eating Disorder.

Start date: August 20, 2018
Phase: N/A
Study type: Interventional

This study aims to develop and evaluate the efficacy of a behavioral weight loss treatment approach for individuals with binge eating disorder to both reduce their binge eating behaviors and lose weight.

NCT ID: NCT03712098 Completed - Smoking Cessation Clinical Trials

Daily Liraglutide for Nicotine Dependence

DAL
Start date: November 29, 2018
Phase: Phase 2
Study type: Interventional

This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain. In this double-blind, placebo-controlled, parallel arm pilot study, overweight and obese smokers (N=40; 20 female and 20 male) will be randomized to 32 weeks of liraglutide or placebo and undergo 8 sessions of smoking cessation behavioral counseling. Outcomes are smoking abstinence and weight change.